Efficacy of Inferrin^TM and Lactoferrin on Symptoms of Irritable Bowel Syndrome in Otherwise Healthy Adults: A Randomised, Double-Blind, Placebo-Controlled Study  

作　　者：David Briskey Amanda Rao David Briskey;Amanda Rao(RDC Clinical, Brisbane, Australia;University of Queensland, Brisbane, Australia)

机构地区：[1]RDC Clinical, Brisbane, Australia [2]University of Queensland, Brisbane, Australia

出　　处：《Food and Nutrition Sciences》2023年第2期59-69,共11页食品与营养科学（英文）

摘　　要：Background: Irritable bowel syndrome affects one in five Australians, with abdominal pain as one of the main symptoms. Lactoferrin, found in milk, is known for its anti-inflammatory properties, and the development of a novel microencapsulated form, Inferrin^TM, may be useful in the treatment of irritable bowel syndrome symptoms. The current study aimed to study the effectiveness of Inferrin^TM compared to lactoferrin and a placebo on irritable bowel syndrome symptoms. Methods: Sixty-eight male and female participants over 18 years of age were recruited to complete 8 weeks of supplementation with either Inferrin^TM, lactoferrin, or a matched placebo. Outcomes were measured at baseline, week 4, and week 8. Results: There was a decrease from baseline across all groups in IBS symptom severity at weeks 4 and 8, as well as improvements in QOL scores. Lactoferrin and Inferrin^TM groups had a significant reduction from baseline to week 8 in weekly stool frequency. Conclusions: Overall, lactoferrin and Inferrin^TM appeared to have an effect in decreasing symptoms of IBS and weekly stool frequency.Background: Irritable bowel syndrome affects one in five Australians, with abdominal pain as one of the main symptoms. Lactoferrin, found in milk, is known for its anti-inflammatory properties, and the development of a novel microencapsulated form, Inferrin^TM, may be useful in the treatment of irritable bowel syndrome symptoms. The current study aimed to study the effectiveness of Inferrin^TM compared to lactoferrin and a placebo on irritable bowel syndrome symptoms. Methods: Sixty-eight male and female participants over 18 years of age were recruited to complete 8 weeks of supplementation with either Inferrin^TM, lactoferrin, or a matched placebo. Outcomes were measured at baseline, week 4, and week 8. Results: There was a decrease from baseline across all groups in IBS symptom severity at weeks 4 and 8, as well as improvements in QOL scores. Lactoferrin and Inferrin^TM groups had a significant reduction from baseline to week 8 in weekly stool frequency. Conclusions: Overall, lactoferrin and Inferrin^TM appeared to have an effect in decreasing symptoms of IBS and weekly stool frequency.

关 键 词：Inferrin LACTOFERRIN Irritable Bowel Syndrome 

分 类 号：R57[医药卫生—消化系统]